Compare Eli Lilly And Co (LLY) vs Nano Dimension Ltd - ADR (NNDM) Price & Performance

Eli Lilly (LLY) trades at $1,223.97, down 0.62% on the day, maintaining strong bullish momentum with consecutive earnings beats and robust revenue growth. The stock shows technical strength above key support levels at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 102.44% ROE. Recent quarterly results exceeded expectations, with Q2 2026 revenue surging 48% to $23 billion driven by Mounjaro and Zepbound demand.

Outlook remains positive with analyst consensus targeting $1,380 and 73% buy ratings, though elevated valuations (P/E 40.8) and regulatory risks around weight-loss drug competition present headwinds. The company's pipeline advancement with retatrutide filing expected in 2027 provides medium-term growth catalysts, but investors should monitor execution risks in the competitive obesity drug market.

NNDM trades at $1.655, up 1.53% today, with a bullish technical signal from moving averages but bearish oscillators. The company reported Q2 2026 EPS of -$0.03, beating expectations, while revenue grew to $102.44M in 2025. However, net income remains deeply negative at -$293.30M, and cash flow from operations is negative. Recent strategic moves include selling MarkForged to Stratasys and cost-saving initiatives to reduce cash burn.

Outlook: Potential upside from strategic divestitures and cost cuts, but high execution risk and persistent losses pose significant challenges. Investors should weigh the low P/B of 0.73 against sustained profitability concerns and shareholder disputes highlighted in recent news.